title: Prediction of delayed recovery from pediatric community-acquired pneumonia.
abstract: BACKGROUND
  If children with community-acquired pneumonia (CAP) do not recover within 48 hours after starting antibiotic therapy, complications are possible and a checkup must be ensured.Aim of the present study was to evaluate the improvement of pediatric CAP, within 48 hours after starting therapy, in relation to age, etiology, clinical/laboratory characteristics and selected antibiotics.
  
  
  METHODS
  Ninety-four children were treated for radiologically confirmed CAP, 64 by oral amoxicillin, 23 by intravenous ampicillin and 7 by other antibiotics. The etiology of CAP was studied by serology, data on more than 20 clinical characteristics were collected retrospectively, and antibiotics were selected on clinical grounds.
  
  
  RESULTS
  After starting of antibiotics, the mean duration of fever was higher in children >or=5 than <2 or 2-4 years of age (p = 0.003). Fever continued >48 hours in 4 (4.3%) children and 2 additional children had empyema. Clinical, radiological and laboratory characteristics and serological findings were not significantly associated with the duration of fever. Fever continued >24 hours in 1 (4.8%) child treated with ampicillin and in 2 (8%) inpatients compared with 19 (28.8%) children treated with amoxicillin (p = 0.007) and 23 (33%) outpatients (p = 0.0012), respectively.
  
  
  CONCLUSIONS
  Respiratory rate and erythrocyte sedimentation rates were associated with rapid decrease of fever. Anyway, none of the reported characteristics was able to predict treatment failures or delayed fever decrease in children suffering from CAP.
authors.affiliation: Pediatric Care Unit, Sant'Antonio General Hospital, San Daniele del Friuli, Udine, Italy. max.don@libero.it
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Don
authors.forename: Francesca
authors.initials: F
authors.lastname: Valent
authors.forename: Mario
authors.initials: M
authors.lastname: Canciani
authors.forename: Matti
authors.initials: M
authors.lastname: Korppi
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007223:Infant; D007558:Italy / Q000453:epidemiology; D008297:Male; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D011024:Pneumonia, Viral / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D011159:Population Surveillance / Q000379:methods*; D011379:Prognosis; D020127:Recovery of Function; D012189:Retrospective Studies; D013997:Time Factors; D055815:Young Adult
chemical_list: D000890:Anti-Infective Agents